Croda International Plc (Croda) offers specialty chemicals to the personal care, healthcare, home care, crop care and industrial specialties markets. It operates through three reportable business segments, Consumer Care, Life Sciences, and Industrial Specialties.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Croda is undertaking various R&D initiatives to gain new scientific and technical knowledge. The company is refocusing innovation by optimizing its approach for different sub-segments. In Core Ingredients, Croda is leveraging its broader skin care expertise for topical applications. In Advanced Ingredients, the company is creating new high-purity excipients for injectables and new bioprocessing aids, supported by a super refining process at its site in Leek, UK. In lipid technologies, Croda is expanding its range of lipids for drug research and targeting further markets, such as the generics segment. The company is also accelerating the development of sustainable vaccine adjuvants with external partners, including sustainable squalene. Croda is advancing its balanced portfolio approach, focusing on strategic innovation and sustainability, while responding to localized trends. The company has launched innovative products like Kerabio, Natrineo CR8, Zenakine, Squalene, and Poloxamer. Croda has strengthened its R&D teams in France and Korea and introduced a new trade secrets framework to protect confidential information. The R&D units of Croda include teams focused on Core Ingredients, Advanced Ingredients, and lipid technologies. These units are responsible for leveraging expertise in skin care, creating high-purity excipients and bioprocessing aids, expanding lipid ranges, and developing sustainable vaccine adjuvants. It holds 1,700 patents. The company has formed a major technology alliance through a recent partnership with Certest to expand its lipid technologies. In FY2025, the company incurred a research and development expenditure of GBP60.2 million which was 3.5% of the company's total revenue and declined 5.4% YoY.